Business Context and Reporting Period
Pavmed Inc., an emerging growth company incorporated in Delaware, filed this Form 8-K on May 15, 2019. The report details a corporate action regarding the adjustment of the conversion price for its outstanding Senior Secured Convertible Note.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The primary financial instrument discussed is the Senior Secured Convertible Note issued on December 27, 2018, with an initial principal amount of $7,750,000.
- Convertible Note Principal: $7,750,000 (initial)
- Initial Conversion Price: $1.60 per share
- Historical Conversions: $599,000 in principal and interest converted into 553,648 shares during prior adjustment periods (March 20–April 9, 2019, and April 23–May 14, 2019).
Material Changes
Effective May 15, 2019, the Company voluntarily reduced the conversion price of the Convertible Note for a limited "Adjustment Period" running through June 4, 2019.
- New Conversion Price: The greater of (i) $1.00 or (ii) 85% of the closing sale price of the common stock on the most recent trading day.
- Conversion Cap: The holder may not convert more than 2,000,000 shares at this reduced price.
- Reversion: After the Adjustment Period ends or the 2,000,000 share cap is reached, the conversion price reverts to $1.60 per share.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the voluntary price reduction mechanism permitted under the Note's terms. The filing indicates a pattern of utilizing this mechanism, having previously reduced the price in March and April 2019. No specific forward-looking guidance, risk factors, or contingencies beyond the terms of the Note are disclosed in this report.
Investor Verification Checklist
- Verify the current outstanding principal balance of the Convertible Note after the $599,000 converted in prior periods.
- Monitor the daily closing stock price during the Adjustment Period (May 15–June 4, 2019) to calculate the effective conversion price.
- Confirm whether the 2,000,000 share conversion cap is reached before June 4, 2019.
- Review the full terms of the December 27, 2018 securities purchase agreement for other potential dilution triggers.